 |
CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. Under the agreement, Ailux Biologics grants Janssen and its affiliates a non-exclusive license to leverage its XtalFoldâ„¢ platform for the discovery and engineering of biologics. XtalFoldâ„¢ is a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases. The agreement was facilitated by Johnson & Johnson Innovation.
XtalFoldâ„¢ utilizes sequence information alone to model the interaction between biomolecules, which forms the foundation of biotherapeutics like monoclonal antibodies. In rigorous benchmark studies, XtalFoldâ„¢ achieved state-of-the-art performance in terms of overall success rate and the quality of hard-to-model regions like the antibody-antigen interface. Since its launch one year ago, XtalFoldâ„¢ has been fully validated in more than 30 partner and internal programs, delivering highly impactful results in a variety of use cases, including antigen design, epitope identification, affinity maturation, pH-sensitivity engineering, and bispecifics design.
Yi (Alex) Li, VP of XtalPi and Head of Ailux Biologics, said: "Biologics are intricate machines that operate in three-dimensional space. XtalFoldâ„¢ enables the visualization and design of biologics in 3D space in real time, which could take months using currently available experimental approaches. We are excited to share with Janssen this foundational technology, which has already proven transformative in-house."
About XtalPi
XtalPi ("QuantumPharm Inc.", stock code: 2228.HK) is a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform company. Established in 2015 by three postdoctoral physicists at Massachusetts Institute of Technology (MIT), the company is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally.
About Ailux Biologics
Ailux Biologics is a division of XtalPi dedicated to the innovation in large molecule drug discovery. With a team of around 100 experts, Ailux has established a state-of-the-art biologics discovery lab, a proprietary database purpose-built for AI (AtlaXâ„¢) and a trio of AI platforms, including a structure modeling suite (XtalFoldâ„¢), a generative large language model for proteins (XenProTâ„¢) and a predictive AI suite for biologics (Xentientâ„¢). Ailux partners with pharma and biotech companies to accelerate their biologics programs with AI-powered, lab-validated solutions. To learn more, visit https://ailuxbio.com/ and follow @Ailux Biologics on Linkedin.
CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. Under the agreement, Ailux Biologics grants Janssen and its affiliates a non-exclusive license to leverage its XtalFoldâ„¢ platform for the discovery and engineering of biologics. XtalFoldâ„¢ is a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases. The agreement was facilitated by Johnson & Johnson Innovation.
XtalFoldâ„¢ utilizes sequence information alone to model the interaction between biomolecules, which forms the foundation of biotherapeutics like monoclonal antibodies. In rigorous benchmark studies, XtalFoldâ„¢ achieved state-of-the-art performance in terms of overall success rate and the quality of hard-to-model regions like the antibody-antigen interface. Since its launch one year ago, XtalFoldâ„¢ has been fully validated in more than 30 partner and internal programs, delivering highly impactful results in a variety of use cases, including antigen design, epitope identification, affinity maturation, pH-sensitivity engineering, and bispecifics design.
Yi (Alex) Li, VP of XtalPi and Head of Ailux Biologics, said: "Biologics are intricate machines that operate in three-dimensional space. XtalFoldâ„¢ enables the visualization and design of biologics in 3D space in real time, which could take months using currently available experimental approaches. We are excited to share with Janssen this foundational technology, which has already proven transformative in-house."
About XtalPi
XtalPi ("QuantumPharm Inc.", stock code: 2228.HK) is a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform company. Established in 2015 by three postdoctoral physicists at Massachusetts Institute of Technology (MIT), the company is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally.
About Ailux Biologics
Ailux Biologics is a division of XtalPi dedicated to the innovation in large molecule drug discovery. With a team of around 100 experts, Ailux has established a state-of-the-art biologics discovery lab, a proprietary database purpose-built for AI (AtlaXâ„¢) and a trio of AI platforms, including a structure modeling suite (XtalFoldâ„¢), a generative large language model for proteins (XenProTâ„¢) and a predictive AI suite for biologics (Xentientâ„¢). Ailux partners with pharma and biotech companies to accelerate their biologics programs with AI-powered, lab-validated solutions. To learn more, visit https://ailuxbio.com/ and follow @Ailux Biologics on Linkedin.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform
TAIPEI, May 28, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, announced the availability of the AORUS MASTER 16 2026, a flagship AI gaming laptop that combines desktop-class performance, advanced cooling, and an exclusive AI agent in an ultra-thin 19mm portable design. Built as a mobile gaming platform to deliver immersive play and AI-powered workflows, it pairs a 16-inch OLED HDR 1000 display with a 240Hz refresh rate and up to 0.2ms response time to balance esports responsiveness with creator-grade color accuracy. It's also recognized with the COMPUTEX 2026 Best Choice Award.
Engineered for demanding workloads, the AORUS MASTER 16 is configurable up to an AMD Ryzen™ 9 9955HX3D processor and up to an NVIDIA® GeForce RTX™ 5090 Laptop GPU, delivering close to desktop-level computing power. The model also supports MUX Switch to simplify integrated GPU or discrete GPU selection with fast mode. With advanced GPU AI capability of up to 1824 AI TOPS, it is built for next-gen AI-assisted creation and accelerated workflow. Leveraged with the flagship WINDFORCE INFINITY EX thermal solution, featuring a vapor chamber design and the integrated Frost Fan 2.0, supports up to 230W system power, helping maintain stable, low-noise performance under sustained loads.
At the center of the experience is GiMATE, GIGABYTE's exclusive AI agent designed for more flexible and intelligent system control. It streamlines performance management and introduces tools for modern workflows. GiMATE Creator integrates generative image models into a manageable local workflow to reduce setup barriers, and GiMATE Coder supports natural-language code generation, correction, and optimization with Visual Studio Code auto-completion to accelerate iteration and debugging.
AORUS MASTER 16 features a 16:10 2.5K 240Hz OLED display with 100% DCI-P3 and a 1,000,000:1 contrast ratio for vivid, creator-accurate visuals. It is backed by certifications including Pantone® Validated, TÜV Rheinland Certified, VESA ClearMR 10000, VESA DisplayHDR 1000, and Dolby Vision®. For audio, Dolby Atmos® and four dual-force speakers with Smart Amplifier deliver a more cinematic experience, while signature touches like AORUS 5-degree Black and RGB lighting add a refined, premium finish for everyday use.
For more information, please visit the official product page. Final configurations and sales timing may vary by region and local retail or e-tail channels.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
GIGABYTE Announces AORUS MASTER 16 Now Available, Built for AI-Powered Performance and Immersive Play
